Amazon Biotech Inc (fka AMZO)

[Renee]

Trendtraderz: Over the last two years the SEC has successfully litigated to revoke over 500 Securities that have refused to file Financials. AMZO hasn't filed any Financials in 4 1/2 years.
The SEC moves very fast once they file an Admin Proceeding to revoke a registration.

I will provide evidence of the 500+ revocations if you request it.

As simple as I can put it, AMZO files Financials immediately, toute-de-suite, right the heck NOW or this stock will likely be revoked within a few weeks.

AMZO will open on the Grey Sheets after the Suspension expires. Although it would be irresponsible for me to suggest that you sell out I know that I would sell as fast as I could if I owned any AMZO stock.

Best o'luck, Trendtraderz....sincerely!!!


Excerpt from the ADMIN Proceeding: Amazon Biotech, Inc. (“AMZO”) (CIK No. 1088781) is an expired Utah corporation located in West Palm Beach, Florida with a class of securities registered with the Commission pursuant to Exchange Act Section 12(g). AMZO is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 10-QSB for the period ended October 31, 2007

More Excerpts:

DELINQUENT PERIODIC FILINGS
7. As discussed in more detail above, all of the Respondents are delinquent in their periodic filings with the Commission, have repeatedly failed to meet their obligations to file timely periodic reports, and failed to heed delinquency letters sent to them by the Division of Corporation Finance requesting compliance with their periodic filing obligations or, through their failure to maintain a valid address on file with the Commission as required by Commission rules, did not receive such letters.

B. Whether it is necessary and appropriate for the protection of investors to suspend for a period not exceeding twelve months, or revoke the registration of each class of securities registered pursuant to Section 12 of the Exchange Act of the Respondents identified in Section II hereof, and any successor under Exchange Act Rules 12b-2 or 12g-3, and any new corporate names of any Respondents.